Using Bayesian analysis in randomised phase II clinical trials to determine the worth of proceeding to phase III

First Author: Billingham L
Attributed to:  Midland Hub for Trials Methodology Research at University of Birmingham funded by MRC

Abstract

No abstract provided

Bibliographic Information

Type: Journal Article/Review

Parent Publication: BMJ